10 Clinical Trials To Look Out For In 2025
Scrip surveys some of the more interesting Phase III clinical trial readouts expected this year.
Scrip surveys some of the more interesting Phase III clinical trial readouts expected this year.
In addition to deregulation, the Economic Survey 2025 highlights the pressing need for greater innovation and R&D in India’s pharmaceutical industry.
Relmada has acquired sepranolone, a potential blockbuster for the complex neurological condition characterized by involuntary tics, for a bargain €3m from the Stockholm group that went into liquidation late last year.
Scrip surveys some of the more interesting Phase III clinical trial readouts expected this year.
The company needs a string of Phase III wins this year to keep on track to reach $80bn revenues in 2030, with analysts still skeptical. Meanwhile, investors were relieved to learn that any fine related to a China corruption probe would be relatively modest.
A revolution is underway. Technology offers the possibility to transform multiple aspects of the traditional gold standard of drug development: the randomized controlled trial. Sharing their insights with Scrip, 30 thought leaders consider how the clinical trial landscape will evolve in 2025.
Sionna essentially doubled its cash on hand with its initial public offering to go up against a formidable competitor in cystic fibrosis with novel medicines applicable to a broad population.
Alumis said it will pause the planned Phase III program for Acelyrin’s lead drug and assess the value of the candidate, which produced underwhelming Phase II results in January.
Relmada has acquired sepranolone, a potential blockbuster for the complex neurological condition characterized by involuntary tics, for a bargain €3m from the Stockholm group that went into liquidation late last year.
US private equity group to buy Japanese pharma firm in a transaction scheduled to close by September that marks owner's exit from pharma.
Plus deals involving Vanda/AnaptysBio, OS Therapies/Ayala, Leveragen/Moonlight Bio, Lantheus/Evergreen, Exicure/GPCR, Arrivent/Lepu, InnoCare/KeyMed/Prolium and more.
What a company says – and does not say – about its outlook can sway sentiment. Meanwhile, the snapshot of a big pharma’s quarterly results offers an insight to the circle of a portfolio’s life, with new products ascending to blockbuster status as previous blockbusters disappear.
Recent moves in the industry include changes at the top at Shanghai Bao Pharmaceutical and Alumis, plus Nurix Therapeutics acquires chief commercial officer from Arvinas.
Public Company Edition: A three-per-month IPO pace would top the 25 first-time biopharma offerings in 2024. Also, Akero grossed $402.5m and 89bio raised $250m in follow-on offerings that cashed in on Akero’s Phase IIb MASH readout. Immunovant raised $450m in a private placement.